Aurobindo Pharma gets USFDA nod for Perampanel

Aurobindo Pharma has received final USFDA approval to manufacture and market Perampanel Tablets in 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg strengths. Key highlights: - Estimated market size: $67 million for the 12 months ended August 2026. - Launch planned for Q3 FY27. - Manufacturing will be undertaken at Unit-IV of APL Healthcare, a wholly owned subsidiary. - Aurobindo Pharma now has 599 USFDA ANDA approvals, comprising 574 final and 25 tentative approvals. - Perampanel is indicated for the treatment of certain seizure disorders associated with epilepsy. Why it matters The approval expands Aurobindo Pharma's US generic portfolio and gives the company access to a market estimated at $67 million. The eventual revenue contribution will depend on launch timing, pricing, competition and market share. What to watch next Investors should track the Q3 FY27 launch, product uptake, pricing, competitive intensity and its contribution to US revenues. Analyst's view: The USFDA approval is a positive business development, while the actual earnings impact will depend on successful commercialisation and market penetration. Learning outcome: Investors should assess a pharma approval by considering market size, launch timeline, competition and potential market share rather than treating regulatory approval alone as an earnings estimate.